Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Department of Public Health, Community Medicine, Jordan University of Science and Technology, Irbid, Jordan.
J Dermatolog Treat. 2022 Feb;33(1):146-149. doi: 10.1080/09546634.2020.1729952. Epub 2020 Feb 21.
The pathogenesis of vitiligo is complex and multifactorial, accumulating evidence of increased oxidative stress and reduction in catalase levels in vitiligo patients has been shown, hence, pseudocatalase/superoxide dismutase (PSD) gel has been used as treatment option for vitiligo.
To assesses the synergic effect of PSD when combines with Tacrolimus 0.1% ointment Tacrolimus 0.1% alone.
A randomized controlled trial that included 49 children with vitiligo with limited area (10% or less). Patients were randomized into two groups: Group 1 (24 patients) were treated only with Tacrolimus 0.1% ointment whereas Group 2 (25 patients) were treated with Tacrolimus 0.1% ointment plus PSD. Degree of repigmentation compared to baseline was assessed at 3, 6, and 9 months.
The median age was 10.05 years (range 2-18). The percentages of pigmentation on 3, 6, and 9 months for Group 1 were 23.9%, 40.4%, and 60%, respectively and for Group 2 were 23.2%, 40.7%, and 62.4%, respectively. There was no significant difference according to repigmentation percentages between the two groups ( > .86, > .97, and > .78, respectively).
The results showed that the addition of PSD to Tacrolimus ointment in children with limited vitiligo was not associated with any therapeutic benefit.
白癜风的发病机制复杂且多因素，已证实白癜风患者存在氧化应激增加和过氧化氢酶水平降低，因此假性过氧化氢酶/超氧化物歧化酶（PSD）凝胶已被用作白癜风的治疗选择。
评估 PSD 与他克莫司 0.1%软膏联合使用时与单独使用他克莫司 0.1%软膏相比的协同作用。
这是一项随机对照试验，纳入了 49 例局限性白癜风（面积<10%）的儿童患者。患者随机分为两组：第 1 组（24 例）仅接受他克莫司 0.1%软膏治疗，第 2 组（25 例）接受他克莫司 0.1%软膏加 PSD 治疗。在 3、6 和 9 个月时评估与基线相比的复色程度。
中位年龄为 10.05 岁（范围 2-18 岁）。第 1 组在 3、6 和 9 个月时的色素沉着百分比分别为 23.9%、40.4%和 60%，第 2 组分别为 23.2%、40.7%和 62.4%。两组之间的复色百分比无显著差异（分别为 > .86、 > .97 和 > .78）。
结果表明，在局限性白癜风儿童中，将 PSD 添加到他克莫司软膏中并没有带来任何治疗益处。
